CPIC

CPIC Successfully Holds the ESG Investment Forum of GBA to Jointly Create a New Situation for the Development of the Bay Area

Retrieved on: 
Monday, February 27, 2023
Tianhe, Speech, Carbon, Road, State-owned Assets Supervision and Administration Commission of the State Council, Bank of Shanghai, ESG, Insurance, Shanghai Industrial Holdings, CICC, CPIC, Bank, Philosophy, Guangdong–Hong Kong–Macao Greater Bay Area, Shanghai Pudong Development Bank, Haitong Securities, Party, Cryptocurrency, Warehouse, Renewable energy, San Francisco Bay Area

At the forum, all guests jointly witnessed the official opening of the headquarters building of CPIC in the Greater Bay Area.

Key Points: 
  • At the forum, all guests jointly witnessed the official opening of the headquarters building of CPIC in the Greater Bay Area.
  • Locating here, the Group aims to actively respond to the national strategy and better serve the real economic and social development of the Bay Area.
  • Kong Qingwei, the Chairman of CPIC said, "The Greater Bay Area is the main battlefield for the regional development of CPIC.
  • The three major strategies have been implemented in the Bay Area market successively, creating a new situation for the Group's development in the Bay Area.

Genetic Toxicology Testing Market Report 2022: Increasing Use Of Pharmacogenomics And Personalized Medicines Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022
Health, Biotechnology, Pathology, Application, CRO, Charles River Laboratories, National Network, USD, Reagent, Industry, Risk, EFSA, Toxicology, Toxicity, Growth, Food, Plant, Acquisition, FDA, Contract research organization, Gene, CAGR, LabCorp, CPIC, Organization, Medical device, Pharmacogenomics

The global genetic toxicology testing market size is expected to reach USD 3.57 billion by 2030.

Key Points: 
  • The global genetic toxicology testing market size is expected to reach USD 3.57 billion by 2030.
  • The rising usage of personalized medicines, combined with the development of cell and gene therapy across the globe is enhancing the demand for genotoxicology.
  • Increasing implementation of pharmacogenomics to support personalized medicine usage and reduced risk of adverse drug toxicity is considered to have a significant impact on the growth of the industry.
  • Hence, these limitations are anticipated to hamper the growth of the genetic toxicology industry.

Global Glass Fiber Market Trends, Opportunities and Competitive Analysis Report 2022-2027 Featuring Owens Corning, Jushi, Nippon Electric, CPIC, and Taishan Fiberglass - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Other Manufacturing, Manufacturing, Wind, Electronics, Glass, Industry, Carbon, Fuel economy in automobiles, Forecast, Population, Growth, International Strategic Analysis, Original equipment manufacturer, CPIC, Government, Transport, Urbanization, Porter's five forces analysis, CAGR, M&A, NEC, Competitive analysis, Retail, Glass fiber

The "Glass Fiber Market: Trends, Opportunities and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glass Fiber Market: Trends, Opportunities and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The global glass fiber market is expected to reach an estimated $17.5 billion by 2027 with a CAGR of 5.0% from 2021 to 2027.
  • Some of the glass fiber companies profiled in this report include Owens Corning, Jushi, Nippon Electric, CPIC, and Taishan Fiberglass.
  • Growth Opportunities: Analysis on growth opportunities in different end use, manufacturing process, product type, and regions for the glass fiber market.

China Glass Fiber Market Report 2022: Market Size, Trends and Growth Analysis Featuring China Jushi, CPIC, Owens Corning, Taishan Fiberglass, and Sichuan Weibo - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Other Manufacturing, Manufacturing, Miniaturization, Electronics, Industry, Forecast, 3D, IOT, Growth, International Strategic Analysis, CPIC, Transport, Porter's five forces analysis, CAGR, M&A, Owens Corning, Adoption, Retail, Glass fiber

The "China Glass Fiber Market: Market Size, Trends and Growth Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Glass Fiber Market: Market Size, Trends and Growth Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Emerging trends, which have a direct impact on the dynamics of the Chinese glass fiber industry, includes innovation trends focused on ultra-high modulus glass fiber and glass fiber based composites part using 3D technology.
  • In this market, E/ECR-glass fiber and S-glass fiber are the major fiber types of Chinese glass fiber market.
  • Growth Opportunities: Analysis on growth opportunities in different end use, manufacturing process, fiber type, and product type for the Chinese glass fiber market.

Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

Retrieved on: 
Wednesday, July 27, 2022
DNA, Death, Acquisition, Diagnosis, Time, Genomics, Laboratory, Genome, Twitter, Instagram, U.S. Securities and Exchange Commission, Genotype, CPIC, SAN, Cardiovascular disease, Agriculture, Solution, ATAC-seq, CVD, Cerebellar ataxia, RNA-Seq, Health, WGS, Transcriptome, Catalog, NASDAQ, Form 10-K, Epigenome, YouTube, Review, Illumina, Inc., Technology, Security (finance), LinkedIn, Lists of diseases, Chromatin, Reproductive health, Efficiency, STR, Population, Research, Facebook, Illumina

SAN DIEGO, July 27, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform. The new features expand laboratories' abilities to perform analyses in key areas such as oncology, pharmacogenomics (PGx), single-cell sequencing, and population genomics within a single platform.  

Key Points: 
  • Illumina DRAGEN is a leading secondary analysis software in the genomics market, and its continuous innovations have set new standards for accuracy and efficiency.
  • With availability across multiple access points, from a standalone server to Illumina cloud solutions and onboard select sequencers, DRAGEN streamlines sequencing data acquisition and analysis.
  • DRAGEN v4.0 unlocks the power of genomics for Illumina customers by providing an expanded suite of capabilities, including:
    Expanded PGx capabilities DRAGEN v4.0 enables the calling of 20 Tier 1 genes (CPIC Level A genes).
  • It also supports the genotyping of complex PGx genes and powers insights for optimal genotype and corresponding metabolism status.

Accidental Death Insurance Global Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 21, 2022
Insurance, Professional Services, Dai, Death, Accident, Bancassurance, Insurance Regulatory and Development Authority, China Life Insurance Company, Sumitomo Life, Awareness, Dai-ichi, Insurance, Blockchain, AXA, European Insurance and Occupational Pensions Authority, NAIC, CPIC, Union, Development, Asia-Pacific, Person, Ping'an, Computer, General Data Protection Regulation, Policy, Unintentional discharge, GDPR, MetLife, National Association of Insurance Commissioners, Accidental, Accenture, Allianz, Pension, CDC, Aegon, Korea Disease Control and Prevention Agency, Center, EIOPA, Life insurance, EU

The "Accidental Death Insurance Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Accidental Death Insurance Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the accidental death insurance market are Allianz, Assicurazioni Generali, China Life Insurance, MetLife, PingAn, AXA, Sumitomo Life Insurance, Aegon, Dai-ichi Mutual Life Insurance, and CPIC.
  • The accidental death insurance market consists of sales of accidental death insurance.
  • The accidental death insurance market is being restrained by a low awareness about life insurance including accidental death insurance.

ADx Health™ Expands Scientific Advisory Board

Retrieved on: 
Monday, June 13, 2022
Sports medicine, Cardiology, PLLC, Boston Marathon, Research, Doctor of Philosophy, Pathology, National College, Neurodegeneration, Boston, Athlete, Duke University School of Medicine, Coronavirus Scientific Advisory Board (Turkey), Genetics, Publication, DNA, CPIC, Naturopathy, SNP, MD, Board Vitals, Board, Health, Pharmaceutical industry

BELLINGHAM, Wash., June 13, 2022 /PRNewswire/ -- ADx Health has recently broadened the list of experts contributing to the company's Scientific Advisory Board, The Board is composed of prominent individuals across a number of fields related to genetics, neurodegenerative diseases, pharmacogenomics, cardiology, sports medicine and naturopathy in support the company's mission to deliver the highest quality consumer-directed genetic and wellness testing.

Key Points: 
  • BELLINGHAM, Wash., June 13, 2022 /PRNewswire/ -- ADx Health has recently broadened the list of experts contributing to the company's Scientific Advisory Board, The Board is composed of prominent individuals across a number of fields related to genetics, neurodegenerative diseases, pharmacogenomics, cardiology, sports medicine and naturopathy in support the company's mission to deliver the highest quality consumer-directed genetic and wellness testing.
  • His deep knowledge of pharmacogenetic variants and testing platforms will further support PGx Complete, the ADx Health offering for drug metabolism.
  • For more information on other ADx Health Scientific Advisory Board Members, go to https://adxhealth.com/about/#our-lab-and-team .
  • ADx Health is a wholly-owned subsidiary of Northwest Pathology, PLLC in Bellingham, Washington.

Flexsus Selects GenXys To Accelerate Precision Medicine Program

Retrieved on: 
Thursday, May 19, 2022
CPIC, Health, Company, Pharmacogenomics, Infection, Patient, Insurance, Solution, Media relations, FDA, Population health, Ecosystem, Interview, Precision medicine, Pharmacist, Computer, Laboratory information management system, Diagnosis, Health information management, Patient safety, Pharmacy, CEO, Medical device, Healthcare, Pharmaceutical industry, Medicine, BC

VANCOUVER, BC, May 19, 2022 /PRNewswire/ -- GenXys Health Care Systems, Inc ., the global leader in precision prescribing software with embedded pharmacogenetic data, recently finalized another customer deal to advance precision medicine initiatives with Ohio-based Flexsus, the laboratory division of FlexHealth .

Key Points: 
  • VANCOUVER, BC, May 19, 2022 /PRNewswire/ -- GenXys Health Care Systems, Inc ., the global leader in precision prescribing software with embedded pharmacogenetic data, recently finalized another customer deal to advance precision medicine initiatives with Ohio-based Flexsus, the laboratory division of FlexHealth .
  • GenXys' award-winning precision prescribing software with embedded pharmacogenetics will ensure differentiated PGx solutions for the Flexsus networked pharmacists and expanded medication review capabilities with PGx inclusion to drive PGx use.
  • GenXys is helping to make marked changes in the way people approach precision medicine in community care.
  • "The GenXys software suite will allow Flexsus to offer unparalleled services to its customers and improve patient safety and treatment response," said Samuel Tang, CEO of Flexsus.

Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

Retrieved on: 
Thursday, May 19, 2022
CPIC, Risk, Suicide, Food, Gene, Pharmacogenomics, Food and Drug Administration, Patient, Pain management, Genetic testing, Health, Legislation, Polypharmacy, Medicare, FDA, SAN, London, Medi-Cal, Industry, Genetics, Awareness, Pharmacotherapy, Conditional sentence, Congress, Standard of care, Adoption, Mental health, Diagnosis, Endocrinology, NYSE, Cardiology, Medicine, Pharmaceutical industry, Medical device, Health insurance, Invitae

SAN FRANCISCO, May 19, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx) Panel which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST). With this launch, Invitae now has one of the most comprehensive commercially available PGx panels in the industry. In addition to mental health medications, the panel aligns with PGx-specific guidelines and published evidence that affects hundreds of commonly used medications, including frequently prescribed medications for high-risk patients in primary care, cardiology, endocrinology, pain management and oncology.

Key Points: 
  • SAN FRANCISCO, May 19, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx) Panel which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST).
  • With this launch, Invitae now has one of the most comprehensive commercially available PGx panels in the industry.
  • The panel aligns with some payer coverage that limits the number of genes covered for mental health.
  • "This trend highlights the need to bring PGx testing into mainstream medical care, making it the standard, especially when treating polypharmacy patients and those with mental health conditions."

CPIC Announces 2021 Sustainability Report

Retrieved on: 
Thursday, March 31, 2022
Zero, Yellow River, Sustainability reporting, Company, Yangtze, Atlanta, Ecology, UN, Poverty, Climate change, Belt, Board, Compliance, ESG, Social responsibility, Social Security, Risk management, China Pacific Insurance Company, Board of directors, Philosophy, Intelligence, Carbon, Government, CPIC, Investment, Sustainable development, Technology, Civilization, International Principles on the Application of Human Rights to Communications Surveillance, Traction, The Company, Sustainable Development Goals, London Stock Exchange, Efficiency, Uncertainty, Insurance, Water, Creativity, Renewable energy

HONG KONG, March 31, 2022 /PRNewswire/ --On March 27, China Pacific Insurance (Group) Co., Ltd. ("CPIC" or the "Company"; Stock Code: 2601.HK, 601601.SH, CPIC.LSE) released its 2021 Sustainability Report.

Key Points: 
  • HONG KONG, March 31, 2022 /PRNewswire/ --On March 27, China Pacific Insurance (Group) Co., Ltd. ("CPIC" or the "Company"; Stock Code: 2601.HK, 601601.SH, CPIC.LSE) released its 2021 Sustainability Report.
  • This is the first sustainability report released by CPIC, based on its 13 consecutive years of social responsibility reports, demonstrating its determination and confidence in committing to sustainable development and building a high-quality development highland, and reflecting the development trend of CPIC focusing on long-term benefits and overall interests.
  • Guided by the support for national strategies, the report presents four sustainable development forces, namely sustainable development traction, support, influence and synergy, which comprehensively summarizes the efforts and contributions made by CPIC in the practice of sustainable development.
  • Facing the challenges of the epidemic and uncertainty, CPIC has formulated a sustainable development strategy guided by advanced sustainable development concepts.